MX9400165A - Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. - Google Patents
Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.Info
- Publication number
- MX9400165A MX9400165A MX9400165A MX9400165A MX9400165A MX 9400165 A MX9400165 A MX 9400165A MX 9400165 A MX9400165 A MX 9400165A MX 9400165 A MX9400165 A MX 9400165A MX 9400165 A MX9400165 A MX 9400165A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- butylergoline
- production
- control
- receptors
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- IGFKDKDYQRZSTL-DTQDAUPPSA-N (6ar,10ar)-9-tert-butyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline Chemical class C1=CC([C@@H]2[C@H](NCC(C2)C(C)(C)C)C2)=C3C2=CNC3=C1 IGFKDKDYQRZSTL-DTQDAUPPSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 101150049660 DRD2 gene Proteins 0.000 abstract 1
- 102000017911 HTR1A Human genes 0.000 abstract 1
- 101150015707 HTR1A gene Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 230000006386 memory function Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000028016 temperature homeostasis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929226967A GB9226967D0 (en) | 1992-12-24 | 1992-12-24 | Serotoninergic ergoline derivatives |
| GB939305696A GB9305696D0 (en) | 1993-03-19 | 1993-03-19 | Scrotoninergic ergoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9400165A true MX9400165A (es) | 1994-07-29 |
Family
ID=26302231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9400165A MX9400165A (es) | 1992-12-24 | 1994-01-03 | Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5430031A (enExample) |
| EP (1) | EP0628042B1 (enExample) |
| JP (1) | JP3337688B2 (enExample) |
| KR (1) | KR100325274B1 (enExample) |
| CN (1) | CN1043230C (enExample) |
| AT (1) | ATE204278T1 (enExample) |
| AU (1) | AU669597B2 (enExample) |
| CA (1) | CA2125288C (enExample) |
| DE (1) | DE69330601T2 (enExample) |
| DK (1) | DK0628042T3 (enExample) |
| ES (1) | ES2162856T3 (enExample) |
| FI (1) | FI943839A7 (enExample) |
| HU (1) | HU220391B (enExample) |
| IL (1) | IL108085A (enExample) |
| MX (1) | MX9400165A (enExample) |
| NZ (1) | NZ258559A (enExample) |
| PL (1) | PL304893A1 (enExample) |
| PT (1) | PT628042E (enExample) |
| RU (1) | RU2131427C1 (enExample) |
| TW (1) | TW252979B (enExample) |
| UA (1) | UA41880C2 (enExample) |
| WO (1) | WO1994014806A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407637D0 (en) | 1994-04-18 | 1994-06-08 | Erba Carlo Spa | Serotoninergic abeo-ergoline derivatives |
| EP1685838A1 (en) * | 2000-08-16 | 2006-08-02 | Pharmacia & Upjohn Company LLC | Compounds for the treatment of addictive disorders |
| AU2001283393B2 (en) * | 2000-08-16 | 2005-09-22 | Pharmacia & Upjohn Company | Compounds for the treatment of addictive disorders |
| AU2002305845B2 (en) | 2001-06-08 | 2006-03-30 | Ipsen Pharma S.A.S. | Somatostatin-dopamine chimeric analogs |
| SI21351A (sl) * | 2002-12-17 | 2004-06-30 | LEK farmacevtska dru�ba d.d. | Zdravljenje odvisnosti od psihostimulansov |
| TWI523863B (zh) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | 體抑素－多巴胺嵌合體類似物 |
| JP2016503402A (ja) | 2012-11-01 | 2016-02-04 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | ソマトスタチン類似体及びそのダイマー |
| CN106866656A (zh) * | 2017-02-28 | 2017-06-20 | 西南交通大学 | 一类麦角碱衍生物及其在预防和治疗精神疾病的用途 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| JP2026525309A (ja) * | 2023-07-14 | 2026-07-29 | ２エイ バイオサイエンシズ、インコーポレイテッド | 置換されたエルゴリン |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2802023A1 (de) * | 1977-01-28 | 1978-08-03 | Sandoz Ag | Neue ergotderivate, ihre herstellung und verwendung |
| US4382940A (en) * | 1979-12-06 | 1983-05-10 | Farmitalia Carlo Erba S.P.A. | Ercoline derivatives and therapeutic compositions having CNS affecting activity |
| GB8714767D0 (en) * | 1987-06-24 | 1987-07-29 | Erba Farmitalia | Egoline derivatives |
| FI76085C (fi) * | 1981-07-21 | 1988-09-09 | Erba Farmitalia | Foerfarande foer framstaellning av ergolinderivat. |
| CH649300A5 (de) * | 1981-08-07 | 1985-05-15 | Sandoz Ag | Ergopeptinderivate, ihre herstellung und verwendung. |
| GB2112382B (en) * | 1981-11-06 | 1985-03-06 | Erba Farmitalia | Ergoline derivatives |
| YU254782A (en) | 1981-12-18 | 1986-10-31 | Schering Ag | Process for making new ergot anilides |
| DE3309493A1 (de) * | 1983-03-14 | 1984-09-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue ergolin-derivate, verfahren zu ihrer herstellung sowie verwendung als arzneimittel |
| PH21123A (en) * | 1983-04-28 | 1987-07-27 | Erba Farmitalia | Ergoline derivatives |
| DE3445784A1 (de) * | 1984-12-13 | 1986-06-26 | Schering AG, Berlin und Bergkamen, 1000 Berlin | Verfahren zur herstellung von ergolin-derivaten |
| GB8501078D0 (en) * | 1985-01-16 | 1985-02-20 | Erba Farmitalia | Piperazin-1-yl-ergo-line derivatives |
| GB8515528D0 (en) * | 1985-06-19 | 1985-07-24 | Erba Farmitalia | Ergoline derivatives |
| DE3533672A1 (de) * | 1985-09-19 | 1987-03-26 | Schering Ag | Neue 12- und 13-substituierte ergolinderivate |
| US4939258A (en) * | 1985-10-01 | 1990-07-03 | Eli Lilly And Company | Cycloalkanol esters of dihydrolysergic acid |
| US4968802A (en) * | 1985-10-01 | 1990-11-06 | Eli Lilly And Company | Process of making alkoxy cycloalkanol esters of dihydrolysergic acid |
| DE3535929A1 (de) * | 1985-10-04 | 1987-04-09 | Schering Ag | 1,2-disubstituierte ergolinderivate |
| GB8612366D0 (en) * | 1986-05-21 | 1986-06-25 | Erba Farmitalia | Ergoline esters |
| DE3620293A1 (de) * | 1986-06-16 | 1987-12-17 | Schering Ag | 1-und/oder 2-substituierte ergolinderivate |
| DE3623438C2 (de) * | 1986-07-10 | 1998-04-09 | Schering Ag | In 2-Stellung mit radioaktivem Iod markierte Ergolinylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Diagnostika |
| GB8702364D0 (en) * | 1987-02-03 | 1987-03-11 | Erba Farmitalia | Ergolinyl heterocycles |
| US4931447A (en) * | 1987-06-15 | 1990-06-05 | Eli Lilly And Company | Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines |
| US4843703A (en) * | 1987-07-07 | 1989-07-04 | Truth Incorporated | Method of assembling a window operator |
| ES2032570T3 (es) * | 1987-11-20 | 1993-02-16 | Farmitalia Carlo Erba S.R.L. | Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe). |
| DE3824659A1 (de) * | 1988-07-15 | 1990-02-08 | Schering Ag | 2-, 12- oder 13-substituierte 3-(8'(alpha)-ergolinyl)-1,1-diethylharnstoffe, ihre herstellung und verwendung in arzneimitteln |
| GB8824744D0 (en) * | 1988-10-21 | 1988-11-30 | Erba Carlo Spa | Antiemesis ergoline derivatives |
| US4902691A (en) * | 1988-12-19 | 1990-02-20 | Eli Lilly And Company | Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors |
| DE3913756A1 (de) * | 1989-04-21 | 1990-10-25 | Schering Ag | 8(beta)-substituierte ergoline, verfahren zu ihrer herstellung und ihre verwendung |
| JPH04504582A (ja) * | 1990-01-25 | 1992-08-13 | フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ | エルゴリン誘導体を製造する方法 |
-
1993
- 1993-11-26 PT PT94901903T patent/PT628042E/pt unknown
- 1993-11-26 ES ES94901903T patent/ES2162856T3/es not_active Expired - Lifetime
- 1993-11-26 RU RU94040382A patent/RU2131427C1/ru not_active IP Right Cessation
- 1993-11-26 CA CA002125288A patent/CA2125288C/en not_active Expired - Fee Related
- 1993-11-26 DE DE69330601T patent/DE69330601T2/de not_active Expired - Fee Related
- 1993-11-26 UA UA94085718A patent/UA41880C2/uk unknown
- 1993-11-26 KR KR1019940702946A patent/KR100325274B1/ko not_active Expired - Fee Related
- 1993-11-26 JP JP51472394A patent/JP3337688B2/ja not_active Expired - Fee Related
- 1993-11-26 AT AT94901903T patent/ATE204278T1/de not_active IP Right Cessation
- 1993-11-26 DK DK94901903T patent/DK0628042T3/da active
- 1993-11-26 TW TW082109975A patent/TW252979B/zh active
- 1993-11-26 HU HU9401951A patent/HU220391B/hu not_active IP Right Cessation
- 1993-11-26 WO PCT/EP1993/003337 patent/WO1994014806A1/en not_active Ceased
- 1993-11-26 NZ NZ258559A patent/NZ258559A/en unknown
- 1993-11-26 EP EP94901903A patent/EP0628042B1/en not_active Expired - Lifetime
- 1993-11-26 AU AU56286/94A patent/AU669597B2/en not_active Ceased
- 1993-11-26 PL PL93304893A patent/PL304893A1/xx unknown
- 1993-12-20 IL IL10808593A patent/IL108085A/en not_active IP Right Cessation
- 1993-12-20 US US08/169,177 patent/US5430031A/en not_active Expired - Fee Related
- 1993-12-23 CN CN93112788A patent/CN1043230C/zh not_active Expired - Fee Related
-
1994
- 1994-01-03 MX MX9400165A patent/MX9400165A/es unknown
- 1994-08-19 FI FI943839A patent/FI943839A7/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US5430031A (en) | 1995-07-04 |
| HU9401951D0 (en) | 1994-09-28 |
| AU669597B2 (en) | 1996-06-13 |
| CA2125288A1 (en) | 1994-07-07 |
| WO1994014806A1 (en) | 1994-07-07 |
| EP0628042A1 (en) | 1994-12-14 |
| CA2125288C (en) | 2004-11-23 |
| DK0628042T3 (da) | 2001-11-12 |
| FI943839A0 (fi) | 1994-08-19 |
| ATE204278T1 (de) | 2001-09-15 |
| NZ258559A (en) | 1996-07-26 |
| PL304893A1 (en) | 1995-01-09 |
| EP0628042B1 (en) | 2001-08-16 |
| JP3337688B2 (ja) | 2002-10-21 |
| JPH07504207A (ja) | 1995-05-11 |
| DE69330601D1 (de) | 2001-09-20 |
| AU5628694A (en) | 1994-07-19 |
| KR950700293A (ko) | 1995-01-16 |
| CN1043230C (zh) | 1999-05-05 |
| IL108085A (en) | 1996-10-16 |
| RU2131427C1 (ru) | 1999-06-10 |
| IL108085A0 (en) | 1994-04-12 |
| UA41880C2 (uk) | 2001-10-15 |
| TW252979B (enExample) | 1995-08-01 |
| KR100325274B1 (ko) | 2002-08-14 |
| FI943839A7 (fi) | 1994-08-19 |
| DE69330601T2 (de) | 2002-07-04 |
| RU94040382A (ru) | 1996-07-10 |
| PT628042E (pt) | 2002-01-30 |
| ES2162856T3 (es) | 2002-01-16 |
| HUT68190A (en) | 1995-05-29 |
| HU220391B (hu) | 2002-01-28 |
| CN1093087A (zh) | 1994-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Macho et al. | Non-pungent capsaicinoids from sweet pepper: synthesis and evaluation of the chemopreventive and anticancer potential | |
| DE69203874T2 (de) | Verwendung von (omega-(4-(2-Pyrimidinyl)-1-piperazinyl)-alkyl)1H-Azolderivate für die Herstellung von Heilmitteln zur Behandlung von Störungen kognitiver Funktionen. | |
| IL109496A (en) | Substituted pyrrolidin-3-yl-alkyl-piperidines process for their preparation and pharmaceutical compositions containing them | |
| IE40025L (en) | DIBENZO [b,d] PYRAN DERIVATIVES | |
| de Angelis et al. | Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice | |
| IL108087A (en) | 2-substituted-3-azaindolyl- acrylonitrile and 3-(azaindolyl-methylene) oxindole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| GT199900054A (es) | Uso de dihidropirimidinas como medicamento y nuevas sustancis. as. | |
| RU94038064A (ru) | Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция | |
| Somlyo et al. | Cyclic adenosine monophosphate: potassium-dependent action on vascular smooth muscle membrane potential | |
| DE3483629D1 (de) | 2-pyrimidinyl-l-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| AR028988A1 (es) | Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas | |
| MX9300603A (es) | Derivados tiaciclicos de piperidinilo. | |
| ATE160344T1 (de) | Heterozyklische alkylamine, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten | |
| ES2102475T3 (es) | Nuevas alquil-amidas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| DE3880601D1 (de) | Steroide mit einem 3,4- oder 6-gliedrigen spiroring in stellung 17, ihre herstellung, zwischenprodukte in ihrer herstellung, ihre anwendung als arzneimittel und pharmazeutische zusammensetzungen, die sie enthalten. | |
| Haas et al. | Pimozide versus haloperidol in acute schizophrenia. A double blind controlled study | |
| CA2164842C (en) | Use of isovaleramide as a mild anxiolytic and mild sedative agent | |
| ES8305714A1 (es) | Procedimiento para la produccion de derivados de piperidile-no | |
| AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
| MX9401080A (es) | Compuestos heteroaromaticos. | |
| CN106831573B (zh) | (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用 | |
| Tobe et al. | Structure–activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-α production and T Cell proliferation | |
| Guandalini et al. | Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs | |
| YU57795A (sh) | Kristalni oblik derivata dihidro-2,3-benzodiazepina |